首页> 美国卫生研究院文献>Springer Open Choice >Dose Conversion Ratio in Hemodialysis Patients Switched from Darbepoetin Alfa to PEG-Epoetin Beta: AFFIRM Study

【2h】

Dose Conversion Ratio in Hemodialysis Patients Switched from Darbepoetin Alfa to PEG-Epoetin Beta: AFFIRM Study

机译：血液透析患者从达比泊汀阿尔法（Darbepoetin Alfa）切换为PEG-Epoetin Beta的剂量转化率：AFFIRM研究

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

IntroductionThere is limited information published on switching erythropoiesis-stimulating agent (ESA) treatment for anemia associated with chronic kidney disease (CKD) from darbepoetin alfa (DA) to methoxy polyethylene glycol-epoetin beta (PEG-Epo) outside the protocol of interventional clinical studies. AFFIRM (Aranesp Efficiency Relative to Mircera) was a retrospective, multi-site, observational study designed to estimate the population mean maintenance dose conversion ratio [DCR; dose ratio achieving comparable hemoglobin level (Hb) between two evaluation periods] in European hemodialysis patients whose treatment was switched from DA to PEG-Epo.

机译：简介关于介入治疗研究以外的协议，关于将红细胞生成刺激剂（ESA）治疗与慢性肾脏疾病（CKD）相关的贫血从达贝泊汀（DA）改为甲氧基聚乙二醇-表皮素β（PEG-Epo）的信息很少。 AFFIRM（相对于Mircera的Aranesp效率）是一项回顾性，多站点，观察性研究，旨在评估人群平均维持剂量转化率[DCR;剂量比率在两个评估期之间达到可比的血红蛋白水平（Hb）]在欧洲血液透析患者中，其治疗从DA改为PEG-Epo。

著录项

期刊名称 Springer Open Choice
作者
Peter Choi; Mourad Farouk; Nick Manamley; Janet Addison;
展开▼
作者单位

展开▼
年(卷),期 -1(30),11
年度 -1
页码 1007–1017
总页数 11
原文格式 PDF
正文语种
中图分类外科学;
关键词
Anemia Chronic kidney disease Darbepoetin alfa Dose conversion Erythropoiesis-stimulating agent Hematology Hemodialysis Medication switching Pegylated erythropoietin beta Retrospective study;

机译：贫血;慢性肾脏病;阿尔贝泊汀;剂量转换;促红细胞生成剂;血液学;血液透析;药物转换;聚乙二醇化促红细胞生成素β;回顾性研究;

相似文献

外文文献
中文文献
专利

1. Dose conversion ratio in hemodialysis patients switched from darbepoetin alfa to PEG-epoetin beta: AFFIRM study [J] . ChoiP., FaroukM., ManamleyN., Advances in therapy. . 2013,第11期

机译：血液透析患者的剂量转换率从darbepoetin alfa改为PEG-epoetin beta：AFFIRM研究
2. Dose Conversion Ratio in Hemodialysis Patients Switched from Darbepoetin Alfa to PEG-Epoetin Beta: AFFIRM Study [J] . Peter Choi, Mourad Farouk, Nick Manamley, Advances in Therapy . 2013,第11期

机译：血液透析患者从达比泊汀阿尔法（Darbepoetin Alfa）切换为PEG-Epoetin Beta的剂量转化率：AFFIRM研究
3. Dose conversion ratio in hemodialysis patients switched from darbepoetin alfa to PEG-epoetin beta: AFFIRM study [J] . ChoiP., FaroukM., ManamleyN., Advances in therapy. . 2013,第11期

机译：血液透析患者的剂量转化比从Darbepoetin Alfa转换为Peg-Epoetin Beta：肯定的研究
4. Iron and ferritin status in hemodialysis patients under darbepoetin alfa therapy [C] . Tokmak, F., Kisters, Workshop on Macro, Trace and Ultratrace Elements; 20040924-25; Jena(DE) . 2004

机译：达贝泊汀α疗法对血液透析患者铁和铁蛋白的影响
5. Understanding off-label utilization patterns of two biotechnology drugs, recombinant erythropoietin alfa and darbepoetin alfa: A multi-hospital study. [D] . Patkar, Anuprita D. 2005

机译：了解两种生物技术药物的标签外利用模式：重组促红细胞生成素α和darbepoetin alfa：一项多院研究。
6. Preservation of Anemia Control and Weekly ESA Dosage After Conversion from PEG-Epoetin Beta to Darbepoetin Alfa in Adult Hemodialysis Patients: The TRANSFORM Study [O] . Jan Donck, Lourdes Gonzalez-Tabares, Jacques Chanliau, -1

机译：从成年血液透析患者的PEG-Epoetin Beta转换为Darbepoetin Alfa后贫血控制和每周ESA剂量的保存：TRANSFORM研究
7. Dose Conversion Ratio in Hemodialysis Patients Switched from Darbepoetin Alfa to PEG-Epoetin Beta: AFFIRM Study [O] . 2013

机译：血液透析患者从达比泊汀阿尔法（Darbepoetin Alfa）切换为PEG-Epoetin Beta的剂量转化率：AFFIRM研究

Dose Conversion Ratio in Hemodialysis Patients Switched from Darbepoetin Alfa to PEG-Epoetin Beta: AFFIRM Study

摘要

著录项

相似文献

相关主题

期刊订阅